As interest in the field of cell-based therapies continues to grow, there is an emerging need to develop sensitive, robust and quantitative methods to track cells in vivo longitudinally, non-invasively and with minimal disturbance of the host environment. Several nuclear imaging techniques have been deployed utilizing both single-photon emission computerized tomography (SPECT) and positron emission tomography (PET). PET offers superior sensitivity to SPECT and thus is the method of choice for tracking small numbers of cells in vivo.
The authors describe the development, synthesis and in vivo application of a novel, biostable 89Zr labeling strategy for PET-based non-invasive longitudinal in vivo cell trafficking.
- synthesis of the novel cell labeling agent 89Zr Desferrioxamine-NCS (89Zr -DBN)
- in vivo imaging of cell traffiking over 7 days using the G4 PET/X-ray system
- Safely work with radioactivity by utilizing proper shielding, dosimetry/monitoring and workflow design
- biodistribution of 89Zr -labeled human Mesenchymal Stem Cells (MSC) in an ischemia/reperfusion mouse model of myocardial infarction (cardiac delivery of cells)